Revolution Medicines, Inc. is a precision oncology company focusing on developing targeted therapies for RAS-addicted cancers. Their pipeline includes RAS(ON) inhibitors and companion inhibitors for combination treatments. The company's key candidates are in various stages of clinical trials.